2017
DOI: 10.1002/ajh.24954
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma

Abstract: Experience with intensive chemotherapy for relapsed/refractory multiple myeloma (RRMM) using VDT PACE regimen and its modifications (VDT PACE-like regimens: VPLRs) outside TOTAL THERAPY trials is limited. We analyzed the outcomes of 141 patients with RRMM who received VPLRs at our center between 2006 and 2017 in an intent-to-treat analysis. Median age was 59.7 years and 66.7% of patients were male. A median of 2.2 years (range 0.02-11.4) separated diagnosis of myeloma and inititation of VPLR. High-risk cytogen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

6
51
1
1

Year Published

2018
2018
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 57 publications
(59 citation statements)
references
References 32 publications
6
51
1
1
Order By: Relevance
“…ere was a trend toward more febrile neutropenia with VTD-PACE and prolonged hospitalization among patients treated with CVAD, but there were no statistically significant differences in adverse events among the 3 regimens [15]. In a retrospective study of 141 patients with RRMM treated with VTD-PACElike regimens, ORR was 54%, OS was 8.1 months, and PFS was 3.1 months [16]. Most patients received 1-2 cycles of a VTD-PACE-like regimen, 85% were refractory to V, and 60% were refractory to R. Patients required a median of 4 packed red cell transfusions and 4 platelet transfusions during cycle 1 [16].…”
Section: Resultsmentioning
confidence: 98%
See 1 more Smart Citation
“…ere was a trend toward more febrile neutropenia with VTD-PACE and prolonged hospitalization among patients treated with CVAD, but there were no statistically significant differences in adverse events among the 3 regimens [15]. In a retrospective study of 141 patients with RRMM treated with VTD-PACElike regimens, ORR was 54%, OS was 8.1 months, and PFS was 3.1 months [16]. Most patients received 1-2 cycles of a VTD-PACE-like regimen, 85% were refractory to V, and 60% were refractory to R. Patients required a median of 4 packed red cell transfusions and 4 platelet transfusions during cycle 1 [16].…”
Section: Resultsmentioning
confidence: 98%
“…In a retrospective study of 141 patients with RRMM treated with VTD-PACElike regimens, ORR was 54%, OS was 8.1 months, and PFS was 3.1 months [16]. Most patients received 1-2 cycles of a VTD-PACE-like regimen, 85% were refractory to V, and 60% were refractory to R. Patients required a median of 4 packed red cell transfusions and 4 platelet transfusions during cycle 1 [16]. Median time to recovery of absolute neutrophil count and platelet count from initiation of a VTD-PACE-like regimen was 18 (range, 12-44) and 21(range 11-45) days, respectively [16].…”
Section: Resultsmentioning
confidence: 99%
“…Patients with an aggressive relapse may need multidrug combinations for effective disease control; VTD-PACE (bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide) [38][39][40] is one such regimen that is now an option listed under "Useful in Certain Circumstances" for treating previously treated aggressive MM (MYEL-D, 3 of 3; page 15).…”
Section: Updates To Maintenance Therapy Recommendationsmentioning
confidence: 99%
“…Standard chemotherapy used on MM as alkylating agents penetrates the BBB very poorly, with only 10% of melphalan levels found at LCR of treated patients [7]. e intensive chemotherapy combinations such as PACE are useful as salvage regimens in refractory/relapsed MM and PCL and appear to be a robust approach to systemic treatment to prevent further hematogenous spread to CNS and elimination of residual clones [46]. As a sole treatment for CNS disease, it is insufficient.…”
Section: Discussionmentioning
confidence: 99%